How did the Feb 27, 2025 $40M offering impact CRDF's short interest percentage?

Cardiff Oncology, Inc. (CRDF) announced a $40 million underwritten registered direct offering on February 27, 2025. The offering was oversubscribed and included participation from both new and existing healthcare-dedicated investors.1

While the offering itself has been confirmed, specific historical data regarding CRDF's short interest percentage for the periods immediately preceding and following February 27, 2025, is not available in the provided search results. Fintel typically publishes short interest data twice monthly, but the available snippets for CRDF's short interest only show daily short sale volume data starting from July 2025 and a current "Short Interest % Float" of 31.75%, without the historical twice-monthly figures needed to assess the offering's impact.1

Without this historical short interest data, it is not possible to determine how the February 27, 2025, offering specifically impacted CRDF's short interest percentage.